- Report
- March 2024
- 180 Pages
Global
From €3262EUR$3,374USD£2,802GBP
€3624EUR$3,749USD£3,113GBP
- Report
- January 2024
- 200 Pages
Global
From €4012EUR$4,150USD£3,446GBP
- Report
- January 2024
- 250 Pages
Global
€4829EUR$4,995USD£4,148GBP
- Report
- October 2021
- 100 Pages
Global
From €5752EUR$5,950USD£4,941GBP
- Report
- October 2019
- 310 Pages
Global
From €3335EUR$3,450USD£2,865GBP
- Report
- June 2019
- 220 Pages
Global
From €2117EUR$2,190USD£1,819GBP
- Report
- July 2022
- 40 Pages
China
From €3094EUR$3,200USD£2,657GBP
Zostavax is a vaccine used to prevent shingles, a painful and debilitating condition caused by the varicella-zoster virus. It is a live attenuated vaccine, meaning it contains a weakened form of the virus. It is approved for use in adults aged 50 and over, and is recommended for those aged 60 and over. Zostavax is administered as a single dose, and is typically given in the upper arm.
The Zostavax market is a subset of the larger vaccine market, which is estimated to be worth billions of dollars. It is a growing market, driven by the increasing prevalence of shingles and the need for effective prevention. The market is highly competitive, with several companies offering their own versions of the vaccine.
Some of the companies in the Zostavax market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and AstraZeneca. Show Less Read more
